2018 Symposium

2017 Symposium

2017 Symposium Photos

2016 Symposium

2015 Symposium

2015 Agenda and Bios

2015 Symposium Photos

2014 Symposium

2014 Agenda and Bios

2013 Featured Talks

2013 Symposium Photos

Previous Symposia

2016 Symposium Featured Talks


Please enjoy the featured talks below from our recent symposium. Thank you!

Please note: These videos are for private viewing only. Any unintended use of the videos without consent is prohibited.

Moores Cancer Center Welcome


Ezra Cohen, MD
UC San Diego Moores Cancer Center




Duane Roth Award


Presented by Council President Sherri Lightner, City of San Diego
Awarded to Dennis Slamon, MD, PhD, UCLA Jonsson Comprehensive Cancer Center


Lung cancer KRAS addiction is reversed by disrupting an integrin/lectin membrane complex


David Cheresh, PhD
UC San Diego Moores Cancer Center



Keynote Presentation: Molecular diversity of human breast cancer: biologic and therapeutic implications


Dennis Slamon, MD, PhD
UCLA Jonsson Comprehensive Cancer Center


Immuno-Oncology: Rational combination therapy


Chris Boshoff, MD, PhD
Pfizer




Detection and targeting of malignant niche mediated cancer stem cell generation


Catriona Jamieson, MD, PhD
UC San Diego Moores Cancer Center



The role of the microenvironment in modulating tumor angiogenesis


Napeoleone Ferrara, MD
UC San Diego Moores Cancer Center



Revisiting matrix metalloproteinases: allosteric inhibition of MMP9 using a monoclonal antibody


Victoria Smith, PhD
Gilead Sciences



The bone niche and therapy resistance in bone metastatic prostate cancer


Christina Jamieson, PhD
UC San Diego Moores Cancer Center



Targeting the PI3K-mTOR signaling circuitry in cancer: a bridge from bench to clinic


J. Silvio Gutkind, PhD
UC San Diego Moores Cancer Center



Anti-ErbB3 therapies – what do we know to date


Birgit Schoeberl, PhD
Merrimack Pharmaceuticals




Immunotherapy Program at UC San Diego Moores Cancer Center


Ezra Cohen, MD
UC San Diego Moores Cancer Center



Compound development of LADD therapeutics in lung cancer


Robert Charnas, PhD
Janssen R&D



Towards personalized immunotherapy of HNSCC


Stephen Schoenberger, PhD
La Jolla Institute for Allergy and Immunology, Human Longevity Inc.



A platform to discover immunotherapeutics for cancer


Judith Varner, PhD
UC San Diego Moores Cancer Center



Biomarker analysis and clinical response in patients with B-cell malignancies treated with anti-CD19 CAR T-cell therapy


Tony Polverino, PhD
Kite Pharma


Partnering with patients to accelerate the pace of biomedical research


Corrie Painter, PhD
Broad Institute of MIT and Harvard



The role of MET exon14 deletion mutations as driver oncogenes in patients with NSCLC and therapeutic intervention with the prototype MET inhibitor glesatinib


James Christensen, PhD
Mirati Therapeutics


Comprehensive genomic profiling of sarcomas in 175 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations


Deborah Morosini, MD
Foundation Medicine


Monitoring daily dynamics of early tumor response to targeted therapy in lung cancer


Hatim Husain, MD
UC San Diego Moores Cancer Center
Mark Erlander, PhD
Trovagene


Closing Remarks


Catriona Jamieson, MD, PhD
UC San Diego Moores Cancer Center




Anti-cancer therapies derived from human pluripotent stem cells


Dan Kaufman, PhD
UC San Diego Moores Cancer Center



Symposium Organizer Welcome


Ida Deichaite, PhD
UC San Diego Moores Cancer Center






KEYNOTE SPEAKERS

Polyvalent vaccines targeting oncogenic driver pathways

Nora Disis, MD

Adjunct Professor of Pathology and Obstetrics and Gynecology
Fred Hutchinson Cancer Research Center
Associate Dean for Translational Science
University of Washington School of Medicine

Molecular diversity of human breast cancer: biologic and therapeutic implications

Dennis Slamon, MD, PhD

Director, Clinical/Translational Research
UCLA Jonsson Comprehensive Cancer Center


FEATURED SPEAKERS

Translational studies of KTN3379, a novel anti-ErbB3 antibody

Diego Alvarado, PhD

Associate Director of Research
Kolltan Pharmaceuticals

Immuno-Oncology: Rational combination therapy

Chris Boshoff, MD, PhD

Vice President, Early Development, Translational and Immuno-Oncology
Pfizer, Inc.

Compound development of LADD therapeutics in prostate and lung cancer

Robert Charnas, PhD

Compound Development Team Leader
Janssen R&D

Lung cancer KRAS addiction is reversed by disrupting an integrin/lectin membrane complex

David Cheresh, PhD

UC San Diego Moores Cancer Center

The role of MET exon14 deletion mutations as driver oncogenes in patients with NSCLC and therapeutic intervention with the prototype MET inhibitor glesatinib

Jamie Christensen, PhD

Chief Scientific Officer
Mirati Therapeutics

Overview

Ezra Cohen, MD

UC San Diego Moores Cancer Center

Monitoring daily dynamics of early tumor response to targeted therapy in lung cancer

Hatim Husain, MD

UC San Diego Moores Cancer Center

Mark Erlander, PhD

Chief Scientific Officer
Trovagene

The role of the microenvironment in modulating tumor angiogenesis

Napoleone Ferrara, MD

UC San Diego Moores Cancer Center

Targeting the PI3K-mTOR signaling circuitry in cancer: a bridge from bench to clinic

J. Silvio Gutkind, PhD

UC San Diego Moores Cancer Center

Detection and targeting of malignant niche mediated cancer stem cell generation

Catriona Jamieson, MD, PhD

UC San Diego Moores Cancer Center

The bone niche and therapy resistance in bone metastatic prostate cancer

Christina Jamieson, PhD

UC San Diego Moores Cancer Center

Anti-cancer therapies derived from human pluripotent stem cells

Dan Kaufman, MD, PhD

UC San Diego Moores Cancer Center

In the wake of homologous repair deficiency: Identifying PARP inhibitor responsive patients

Keith Mikule, PhD

Director, Preclinical Research
TESARO

Comprehensive genomic profiling of sarcomas in 175 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations

Deborah Morosini, MD

Vice President, Clinical Affairs and Patient Engagement
Foundation Medicine

Partnering with patients to accelerate the pace of biomedical research

Corrie Painter, PhD

Associate Director of Operations and Scientific Outreach
Broad Institute of MIT and Harvard

Biomarker analysis and clinical response in patients with B-cell malignancies treated with anti-CD19 CAR T-cell therapy

Tony Polverino, PhD

Vice President, Research
Kite Pharma

Anti-ErbB3 therapies – what do we know to date

Birgit Schoeberl, PhD

SVP, Head of Discovery
Merrimack

Towards personalized immunotherapy of HNSCC

Stephen Schoenberger, PhD

Professor, Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology
Head of Cancer Vaccines, Human Longevity Inc.

Revisiting matrix metalloproteinases: allosteric inhibition of MMP9 using a monoclonal antibody

Victoria Smith, PhD

Senior Director, Biology
Gilead Sciences

A platform to discover immunotherapeutics for cancer

Judith Varner, PhD

UC San Diego Moores Cancer Center




“When you go to an international cancer symposium with 30,000 people, it’s hard to get to the real champion of a project and get their individualized attention. The Moores Cancer Center Translational Oncology Symposium is much more intimate. Industry and academia are on equal footing and there are plenty of opportunities for informal discussions when a lot of synergies develop and collaborations begin or grow.”

- Catriona Jamieson, Ph.D., M.D.,
Director of Stem Cell Research at Moores Cancer Center


The MCC Translational Oncology Symposium is designed as an international forum to foster introductions, stimulate productive conversations among people of complementary interests and galvanize collaborations that will have a profound impact on patient health. It’s a melding of minds in the field of cancer research. Represented will be many of the different skill sets needed to bring a new drug to market – from the lab, through the commercialization process to the patient’s bedside.

Hear from global thought leaders in some of the most promising frontiers of research and treatment, including immunotherapy, antibodies and personalized medicine. Meet top academic researchers, renowned clinicians, and top business development professionals and scientists from the world’s leading pharmaceutical companies and innovative biotechnology companies working in oncology.

In a global environment of budget cuts, including investment in scientific research, industry/academia collaborations are crucial to leverage resources and expertise. In its first ten years, the MCC Translational Oncology Symposium has shown great success in forging collaborations that are speeding drug development times and saving lives:

  • Collaboration between Pfizer and MCC led to a multisite international clinical trial of a sonic hedgehog inhibitor. One patient who was told she had just months to live is alive three years later and has undergone a bone marrow transplant after participating in the trial.
  • Collaboration between San Diego-based TargeGen, MCC and Stanford University, which sped the development of a JAK2 inhibitor and led to the acquisition of TargeGen.




Symposium Organizers and Chairs


Symposium Organizers:

Scott Lippman, MD
Director
UCSD Moores Cancer Center


Symposium Chair:

David Cheresh, PhD
Associate Director for Innovation and Industry Alliances,
Distinguished Professor of Pathology
UCSD Moores Cancer Center



Ida Deichaite, PhD
Director, Industry Relations
UCSD Moores Cancer Center


Symposium Co-Chair:

Catriona Jamieson, MD, PhD
Associate Professor of Medicine,
Chief, Division of Regenerative Medicine
Deputy Director, Sanford Stem Cell Clinical Center
Director, Moores Cancer Center Stem Cell Research Program UCSD Moores Cancer Center










We Thank Our Sponsors: